Pfizer Desperately Outbids for Medivation & Xtandi (NYSE:PFE) (NASDAQ:MDVN)

- August 22, 2016

Pfizer PFE stockI realize that Medivation (NASDAQ:MDVN) has been the hot ticket biotech company for acquirers, but Pfizer (NYSE:PFE) was the last company that needed to pay $14 billion to acquire it.

Fact is that just about every large pharmaceutical and biotech company made a run at Medivation. The big gain is Medivation’s prostate cancer drug Xtandi, and also a pipeline of cancer fighting drugs that MDVN has acquired over the last few years.

The reason Pfizer shouldn’t have acquired Medivation has less to do with MDVN itself and more to do with PFE.

$14 billion is a lot of PFE stock buybacks

For one, PFE stock has a really good thing going right now, recently surging to multi-year highs. And while its revenue is nowhere near record levels, it’s expected sales of $52.85 billion does represent an 8% increase over last year. Moreover, analysts expect growth of 3.4% next year.

With operating margins over 25%, Pfizer creates big earnings that it then uses for stock buybacks and dividends. At just 13x forward earnings, buybacks have a great effect on PFE stock.

What Pfizer gets in exchange for $14 billion is a drug, Xtandi, that had U.S sales of $330.3 million and growth of 11%; ex-US sales of $265 million, +41% year-over-year. Unfortunately, Astellas reports sales on Xtandi, and Medivation’s share created revenue of only $206.2 million with growth of 17.4%.

In other words, Pfizer is getting a share of Xtandi for $14 billion. Pfizer will be lucky if that share produces revenue of $2 billion ever, seeing as how Xtandi already controls 51% of its very competitive market. Therefore, I can’t understand why Pfizer would use up so much cash on a company that won’t add more than 3% to its top-line. It does not make sense. That’s capital PFE could use for dividends and buybacks.

Will MDVN, Xtandi purchase hurt Pfizer?

Medivation Xtandi MDVNThat said, MDVN stock cheerleaders will say that Medivation is trying to cure cancer, and has a robust pipeline. Those same people will say that Pfizer needed a stronger presence in oncology. While true, there are also a lot of companies trying to cure cancer and I’m not certain that Medivation gives Pfizer some big edge.

In addition to a share of Xtandi, Pfizer will gain a Phase 3 breast cancer drug called MDV3800 that Medivation bought from BioMarin for $410 million. Pfizer will get another that fights blood cancer called MDV9300; it paid $5 million upfront and still owes $330 million in milestone payments. Based on these valuations, I don’t think either will be the next Herceptin or Revlimid. Usually, the market identifies breakthrough cancer drugs quickly, which are then assigned massive multi-billion dollar valuations (CAR-T developers).

Ultimately, Pfizer is big enough where I don’t think the MDVN buyout will hurt PFE stock. However, it could cost the company 5-6% of upside when you consider the effect that $14 billion in buybacks would have on PFE stock. After failed acquisition attempts, it is quite obvious that Pfizer was desperate to get a deal done, and paid a premium to ensure it won the bidding war. Thankfully, Pfizer is rich in cash, but even with cash, PFE had no reason to reach for MDVN stock at such a big premium, or any premium at all.

This entry was posted in Healthcare & Biotech, Mergers & Acquisitions Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

4 Trackbacks

  1. […] including Actavis, Allergan (NYSE:AGN), and Covidien, which make Pfizer’s (NYSE:PFE) recent $14 billion purchase of Medivation seem small. Had Pfizer gotten its way, it would have completed the largest merger in […]

  2. […] for Medivation that ultimately resulted in Pfizer paying $14 billion. It was a price that will very unlikely create value for Pfizer stock […]

  3. rainstoppers 68-inch oversize windproof golf umbrella

    Pfizer Desperately Outbids for Medivation & Xtandi (NYSE:PFE) (NASDAQ:MDVN)

  4. […] previously explained, Pfizer’s acquisition of Medivation was to gain ownership of the cancer drug Xtandi, which […]

Post a Comment

You must be logged in to post a comment.







Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.


Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!

%d bloggers like this: